Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Jenscare Scientific Co. Ltd. Class H ( (HK:9877) ) has provided an announcement.
Jenscare Scientific has announced that its iJensRobo robot-assisted transcatheter tricuspid valve replacement system has successfully completed its first clinical study in Hong Kong. In the procedure, the system was used to implant a LuX-Valve Plus prosthetic valve in a patient with severe tricuspid regurgitation, with post-operative imaging showing complete resolution of regurgitation and a well-anchored, stable valve.
iJensRobo is designed as an innovative robot-assisted interventional platform that uses high-precision motion control, active safety constraints and intelligent navigation to offer more stable, precise and controllable support than conventional manual TTVR. Featuring a master-slave architecture that reduces operator radiation exposure and enabling remote operation for potential cross-regional collaboration and training, the system underscores Jenscare’s push into next-generation robotic cardiac interventions, though there is no assurance it will ultimately be commercialized successfully.
More about Jenscare Scientific Co. Ltd. Class H
Jenscare Scientific Co., Ltd. is a China-based medical device company listed in Hong Kong that focuses on innovative interventional cardiovascular therapies. The Group develops advanced catheter-based systems and related robotic platforms targeting structural heart diseases, aiming to improve the precision, safety and consistency of minimally invasive valve procedures.
Average Trading Volume: 203,936
Technical Sentiment Signal: Buy
Current Market Cap: HK$5.44B
Learn more about 9877 stock on TipRanks’ Stock Analysis page.